AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1867449 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula (Isomil)
Number of subjects: 288
Study 7034840 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 20
Study 7034840 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 20
Study 31483544 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day)
Number of subjects: 7
Study 31483544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30137664 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab (0.25, 0.5, and 0.8 mg kg‐1, once every 4 days)
Number of subjects: 24
Study 30137664 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab (highest dose cohort)
Number of subjects: 24
Study 30137664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (3 sessions of 40 minutes each for 2 weeks)
Number of subjects: 50
Study 27904632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 50
Study 27904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50
Study 27904632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 24467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 512
Study 24467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 512
Study 24467549 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg
Number of subjects: 512
Study 23148736 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem (7-day course, 1g as a four-hour infusion every eight hours)
Number of subjects: 274
Study 23148736 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (10-day course, 1g as a one-hour infusion every eight hours)
Number of subjects: 274
Study 21051181 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block with nerve stimulator
Number of subjects: 184
Study 21051181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spielberger test for anxiety assessment
Number of subjects: 184
Study 17126588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable lenses of varying thicknesses (0.18, 0.12, 0.16, 0.20, 0.24, 0.28, and 0.32 mm)
Number of subjects: 14
Study 17126588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) contact lens
Number of subjects: 14
Study 17126588 — intervention group
Group type: COMPARATOR
Intervention: Normal open eye
Number of subjects: 14
Study 17126588 — intervention group
Group type: EXPERIMENTAL
Intervention: Static wear of lenses
Number of subjects: 14
Study 15857205 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (2,000 mg/day)
Number of subjects: 0
Study 15857205 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (1,000 mg/day)
Number of subjects: 0
Study 15857205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11972740 — intervention group
Group type: COMPARATOR
Intervention: Formula with 0.4% ALA
Number of subjects: 44
Study 11972740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.0% ALA
Number of subjects: 44
Study 11972740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.7% ALA
Number of subjects: 44
Study 11972740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 3.2% ALA
Number of subjects: 44
Study 10466547 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV combination vaccine containing 10 microg of HBsAg
Number of subjects: 0
Study 10466547 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV combination vaccine containing 5 microg of HBsAg
Number of subjects: 0
Study 10466547 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTPw and HBV (10 microg of HBsAg)
Number of subjects: 0
Study 7838634 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice flour-ORS (RF-ORS)
Number of subjects: 146
Study 7838634 — intervention group
Group type: COMPARATOR
Intervention: Glucose-ORS (G-ORS)
Number of subjects: 146
Study 7838634 — intervention group
Group type: COMPARATOR
Intervention: Rice dextrin-ORS (RD-ORS)
Number of subjects: 146
Study 7838634 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (RF-ORS, G-ORS, RD-ORS)
Number of subjects: 146
Study 2244843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (antiplatelet agent)
Number of subjects: 435
Study 2244843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 386494 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 54
Study 386494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 54
Study 386494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31960259 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 3084
Study 31960259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3084
Study 30836195 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF therapy (immediate post-surgery for 6 hours, then 3 hours for the next 6 days, and 1.5 hours for days 8-13)
Number of subjects: 32
Study 30836195 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (no extra treatment)
Number of subjects: 32
Study 30836195 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF therapy
Number of subjects: 32
Study 28953308 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-View
Number of subjects: 50
Study 28953308 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 50
Study 25829374 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) using a patient decision aid
Number of subjects: 0
Study 25829374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 0
Study 25128922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar corticotomy
Number of subjects: 30
Study 25128922 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional technique)
Number of subjects: 30
Study 22521233 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (flexible dose of one of five antipsychotic medications)
Number of subjects: 0
Study 19081265 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLM intervention group (n=29)
Number of subjects: 51
Study 19081265 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation group (n=22)
Number of subjects: 51
Study 19081265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 17907491 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 45
Study 17907491 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 45
Study 17907491 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 45
Study 15196297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 22
Study 15196297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 12202464 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study 10102948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 2 weeks
Number of subjects: 205
Study 10102948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4 weeks
Number of subjects: 205
Study 10102948 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 2 weeks
Number of subjects: 205
Study 10102948 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4 weeks
Number of subjects: 205
Study 10102948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 205
Study 10102948 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 205
Study 7480102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-coated tablet formulation containing 50 mg standardized horse chestnut seed extract
Number of subjects: 18
Study 7480102 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation in capsule form containing 50 mg standardized horse chestnut seed extract
Number of subjects: 18
Study 1702449 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (mifepristone)
Number of subjects: 0
Study 7389382 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg pivampicillin twice daily
Number of subjects: 106
Study 7389382 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin 3-times daily
Number of subjects: 106
Study 7389382 — intervention group
Group type: COMPARATOR
Intervention: 100 mg doxycycline daily
Number of subjects: 106
Study 31350847 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFreSP (high-frequency sub-pathways mining approach)
Number of subjects: 8137
Study 31350847 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFreSP
Number of subjects: 8137
Study 31315871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 176
Study 31315871 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding from industry
Number of subjects: 176
Study 31315871 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Quality Score (OQS)
Number of subjects: 176
Study 31315871 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality items (objective, conclusions, funding)
Number of subjects: 176
Study 31315871 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors, randomisation, outcome reporting
Number of subjects: 176
Study 27324087 — intervention group
Group type: EXPERIMENTAL
Intervention: Report cards with numerical design
Number of subjects: 1350
Study 27324087 — intervention group
Group type: COMPARATOR
Intervention: Report cards with textual information
Number of subjects: 1350
Study 27324087 — intervention group
Group type: COMPARATOR
Intervention: Report cards with star ratings
Number of subjects: 1350
Study 27324087 — intervention group
Group type: COMPARATOR
Intervention: Report cards without narrative comments
Number of subjects: 1350
Study 27324087 — intervention group
Group type: EXPERIMENTAL
Intervention: Report cards with narrative comments
Number of subjects: 1350
Study 26002889 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (8 L/min)
Number of subjects: 441
Study 26002889 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen
Number of subjects: 441
Study 24169081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once daily
Number of subjects: 423
Study 24169081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand
Number of subjects: 423
Study 24169081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 22708612 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (observation and immediate imitation of common daily hand and arm actions)
Number of subjects: 0
Study 22708612 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 22708612 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation without any trial-related treatment
Number of subjects: 0
Study 19630125 — intervention group
Group type: EXPERIMENTAL
Intervention: One leg cycling aerobic training program
Number of subjects: 24
Study 19630125 — intervention group
Group type: COMPARATOR
Intervention: Control group (without cardiorespiratory training)
Number of subjects: 24
Study 17560448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum-submission guidance
Number of subjects: 1494
Study 17560448 — intervention group
Group type: COMPARATOR
Intervention: No specific guidance (control)
Number of subjects: 1494
Study 17560448 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions for men
Number of subjects: 1494
Study 15366525 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin cup therapy
Number of subjects: 0
Study 11254519 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP(FOT)
Number of subjects: 52
Study 11254519 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 52
Study 11564007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 881
Study 11564007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 881
Study 11564007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 881
Study 11564007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (both dosages)
Number of subjects: 881
Study 11564007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 881
Study 9216951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low group (living at moderate altitude 2,500 m and training at low altitude 1,250 m)
Number of subjects: 39
Study 9216951 — intervention group
Group type: COMPARATOR
Intervention: High-high group (living and training at moderate altitude 2,500 m)
Number of subjects: 39
Study 9216951 — intervention group
Group type: COMPARATOR
Intervention: Low-low group (living and training in a mountain environment at sea level 150 m)
Number of subjects: 39
Study 8122739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation for three minutes with 100% oxygen ventilation
Number of subjects: 80
Study 8122739 — intervention group
Group type: COMPARATOR
Intervention: No preoxygenation with 100% oxygen ventilation
Number of subjects: 80
Study 8122739 — intervention group
Group type: COMPARATOR
Intervention: No preoxygenation with 50% oxygen ventilation
Number of subjects: 80
Study 8122739 — intervention group
Group type: COMPARATOR
Intervention: No preoxygenation with 33% oxygen ventilation
Number of subjects: 80
Study 3310569 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 160 mg/day)
Number of subjects: 15
Study 3310569 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (400 mg/day)
Number of subjects: 15
Study 1704983 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine plus metoprolol 10 + 100 mg (FM)
Number of subjects: 159
Study 1704983 — intervention group
Group type: COMPARATOR
Intervention: Felodipine 10 mg (F)
Number of subjects: 159
Study 1704983 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg (M)
Number of subjects: 159
Study 1704983 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine plus metoprolol (FM)
Number of subjects: 159
Study 168121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adrenocorticotropic hormone (ACTH)
Number of subjects: 22
Study 168121 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone
Number of subjects: 22
Study 31618446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and/or mirtazapine
Number of subjects: 2011
Study 27600280 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin-bevacizumab (PCB) with nitroglycerin patches
Number of subjects: 223
Study 27600280 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-carboplatin-bevacizumab (PCB) without nitroglycerin patches (control)
Number of subjects: 223
Study 26376600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 801
Study 26376600 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 801
Study 24419513 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (QD) administration of intra-venous (IV) BU
Number of subjects: 0
Study 24419513 — intervention group
Group type: COMPARATOR
Intervention: Four-times-daily (4QD) administration of intra-venous (IV) BU
Number of subjects: 0
Study 21905890 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained prostheses (SP)
Number of subjects: 40
Study 21905890 — intervention group
Group type: COMPARATOR
Intervention: Cemented prostheses (CP)
Number of subjects: 40
Study 21905890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented prostheses (CP) and Screw-retained prostheses (SP)
Number of subjects: 40
Study 19237406 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised consultation
Number of subjects: 336
Study 19237406 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study 17880350 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced appraisals of past harm from baseline to end of treatment
Number of subjects: 252
Study 17880350 — intervention group
Group type: COMPARATOR
Intervention: Increased harm appraisals from baseline to end of treatment
Number of subjects: 252
Study 17880350 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher treatment intensity and 12-step affiliation
Number of subjects: 252
Study 15144668 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft of acellular allo-dermis matrix (ADM) with thin auto-microskin
Number of subjects: 8
Study 15144668 — intervention group
Group type: COMPARATOR
Intervention: Auto-microskin grafted
Number of subjects: 8
Study 11834118 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Closed Kinetic Chain (MCKC) knee extension exercises
Number of subjects: 8
Study 11834118 — intervention group
Group type: COMPARATOR
Intervention: Traditional Open Kinetic Chain (OKC) knee extension exercises
Number of subjects: 8
Study 9806528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate radiotherapy
Number of subjects: 17
Study 9806528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder and rectal volumes
Number of subjects: 17
Study 9806528 — intervention group
Group type: EXPERIMENTAL
Intervention: Margins between the CTV and PTV
Number of subjects: 17
Study 8548939 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment in TBII negative patients (Group A)
Number of subjects: 94
Study 8548939 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment in TBII positive patients (Group B)
Number of subjects: 94
Study 8548939 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) - TBII positive patients
Number of subjects: 94
Study 8548939 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TBII levels
Number of subjects: 94
Study 8548939 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TSAb levels
Number of subjects: 94
Study 8548939 — intervention group
Group type: COMPARATOR
Intervention: Thyroid volumes
Number of subjects: 94
Study 2173354 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term diazepam treatment
Number of subjects: 0
Study 2173354 — intervention group
Group type: COMPARATOR
Intervention: Acute i.v. diazepam administration
Number of subjects: 0
Study 2173354 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 687499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 687499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine plus propranolol
Number of subjects: 0
Study 687499 — intervention group
Group type: COMPARATOR
Intervention: Control period (cold pressor test)
Number of subjects: 0
Study 687499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol during cold pressor test
Number of subjects: 0
Study 687499 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine
Number of subjects: 0
Study 29963733 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval aerobic training programme with active recovery bouts (IATP-R)
Number of subjects: 60
Study 29963733 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 60
Study 27882605 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kgBM caffeine (CAF)
Number of subjects: 42
Study 27882605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 42
Study 27882605 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study 25830782 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk@WorkSpain (W@WS) intervention
Number of subjects: 264
Study 25830782 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (maintained normal behavior)
Number of subjects: 264
Study 23998234 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of docosahexaenoic acid
Number of subjects: 613
Study 23998234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 21430660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab infusion
Number of subjects: 12
Study 19739914 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help memory training program
Number of subjects: 0
Study 19739914 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based memory training program
Number of subjects: 0
Study 19739914 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 18180893 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Liyan Decoction (QRLYD)
Number of subjects: 60
Study 18180893 — intervention group
Group type: COMPARATOR
Intervention: Dobell's solution (Control)
Number of subjects: 60
Study 14745658 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg) and Fluticasone (250 microg) in a single dry powder inhaler (Diskus)
Number of subjects: 365
Study 14745658 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (500 microg) twice daily
Number of subjects: 365
Study 11207464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 50 mg with adrenaline
Number of subjects: 22
Study 11207464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg with adrenaline
Number of subjects: 22
Study 11207464 — intervention group
Group type: COMPARATOR
Intervention: Saline/adrenaline
Number of subjects: 22
Study 9435413 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buccal tablet containing 10 mg testosterone
Number of subjects: 13
Study 9435413 — intervention group
Group type: COMPARATOR
Intervention: Buccal placebo tablet containing 3 mg pseudoephedrine HCl for taste matching
Number of subjects: 13